Clinical Trials Logo

Clinical Trial Summary

This is an open-label phase 1 study with an escalation part and an expansion part.


Clinical Trial Description

The escalation part will evaluate the safety, tolerability, PK and recommended dose of expansion (RDE) of oral ABSK-011 in patients with advanced solid tumors. The expansion part of oral ABSK-011 at RDE will be followed for further evaluating safety and tolerability in patients with FGF19 overexpression advanced HCC. Preliminary antitumor activity will also be assessed. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04906434
Study type Interventional
Source Abbisko Therapeutics Co, Ltd
Contact Yuan Lu, Doctor
Phone +86021-68910052
Email clinical@abbisko.cn
Status Recruiting
Phase Phase 1
Start date February 26, 2020
Completion date August 31, 2025

See also
  Status Clinical Trial Phase
Completed NCT01754987 - A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective Phase 1/Phase 2
Recruiting NCT05698459 - OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients With Advanced Liver Cancer Phase 1
Recruiting NCT03146637 - Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer Phase 2
Withdrawn NCT03484962 - Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer Phase 2
Recruiting NCT05603039 - A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT04163237 - Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer Phase 3
Recruiting NCT02862613 - Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer Phase 1/Phase 2
Recruiting NCT02873442 - Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer Phase 1/Phase 2
Recruiting NCT03474822 - Plasmodium Immunotherapy for Breast and Liver Cancers Phase 1/Phase 2